[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors]. 1985

H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009946 Organothiophosphorus Compounds Compounds containing carbon-phosphorus bonds in which the phosphorus component is also bonded to one or more sulfur atoms. Many of these compounds function as CHOLINERGIC AGENTS and as INSECTICIDES. Compounds, Organothiophosphorus
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010386 Pelvic Neoplasms Tumors or cancer of the pelvic region. Cancer of Pelvis,Pelvic Cancer,Cancer of the Pelvis,Neoplasms of Pelvis,Pelvis Cancer,Pelvis Neoplasms,Cancer, Pelvic,Cancer, Pelvis,Cancers, Pelvic,Cancers, Pelvis,Neoplasm, Pelvic,Neoplasm, Pelvis,Neoplasms, Pelvic,Neoplasms, Pelvis,Pelvic Cancers,Pelvic Neoplasm,Pelvis Cancers,Pelvis Neoplasm
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
May 1983, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
September 1978, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
January 2018, Journal of drugs in dermatology : JDD,
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
January 2010, Dermatology (Basel, Switzerland),
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
April 2012, The Journal of dermatological treatment,
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
January 1999, International journal of clinical pharmacology and therapeutics,
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
January 1989, Clinical therapeutics,
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
March 1970, Hospital (Rio de Janeiro, Brazil),
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
March 2003, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
H Niibe, and I Takahashi, and K Miyaishi, and N Mitsuhashi, and Y Maehara, and N Nakajima, and H Suto, and Y Saito, and M Yamakawa, and S Sugiyama
November 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!